Study: No difference in results by race with standard heart failure treatment

A traditional treatment for heart failure appears to be equally protective in preventing death or hospitalization among African-American patients, as compared to white patients, according to a study at Henry Ford Hospital in Detroit.

Angiotensin converting enzyme inhibitors (ACE) and angiotensin (ARB) are standard treatments. However, they have been shown to be less effective for in African Americans when compared to white patients, and most heart failure studies have enrolled a low proportion of African Americans.

"Although previous data have been somewhat conflicting regarding the consistency of benefits of ACE/ARB across races, this study showed that the results were virtually the same for African-American compared to white patients." says Henry Ford researcher and cardiologist David Lanfear, M.D., lead author of the study.

The results will be presented May 9 at the American Heart Association's annual Quality of Care and Outcomes Research meeting (QCOR12) in Atlanta.

The retrospective study looked at insured patients who were hospitalized for heart failure at Henry Ford Hospital between January 2000 and June 2008, and who primarily received care through the Henry Ford Medical Group.

Using pharmacy claims data, the researchers were able to see the dosage and patients' adherence in filling prescriptions, and could therefore estimate the exposure to medications over time, as well as test the connection to the patients' outcomes. ACE/ARB exposure was estimated over six-month rolling periods.

A total of 1,094 patients (476 White and 618 African-Americans) were studied. The average time of follow-up was two years.

Results were adjusted for other important factors, such as gender, age, other diseases and medications (including beta blockers), in order to identify the effect specifically attributable to taking ACE/ARB medications. Data was analyzed and sorted by race.

Related Stories

Recommended for you

Race influences warfarin dose, study says

date 51 minutes ago

A new report demonstrates that clinical and genetic factors affecting dose requirements for warfarin vary by race. The study, published online today in Blood, the Journal of the American Society of Hematology (ASH), propose ...

Even moderate BMI reduction could ease A-fib burden

date 3 hours ago

(HealthDay)—Incremental increases in body mass index (BMI) are associated with excess risk of incident, postoperative, and post-ablation atrial fibrillation (AF), according to a review published online ...

Personalized saline may provide solution to heart death

date 5 hours ago

Saline solution is a staple of every hospital. No matter the ailment, doctors have known for more than a century that saline is key to keeping patients hydrated and maintaining their blood pressure levels. ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.